Logo image of CRBU

CARIBOU BIOSCIENCES INC (CRBU) Stock Fundamental Analysis

NASDAQ:CRBU - Nasdaq - US1420381089 - Common Stock - Currency: USD

1.12  +0.01 (+0.9%)

After market: 1.13 +0.01 (+0.89%)

Fundamental Rating

3

Taking everything into account, CRBU scores 3 out of 10 in our fundamental rating. CRBU was compared to 557 industry peers in the Biotechnology industry. CRBU has a great financial health rating, but its profitability evaluates not so good. CRBU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRBU had negative earnings in the past year.
CRBU had a negative operating cash flow in the past year.
CRBU had negative earnings in each of the past 5 years.
In the past 5 years CRBU always reported negative operating cash flow.
CRBU Yearly Net Income VS EBIT VS OCF VS FCFCRBU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CRBU has a Return On Assets (-54.03%) which is in line with its industry peers.
CRBU has a Return On Equity of -68.07%. This is comparable to the rest of the industry: CRBU outperforms 56.37% of its industry peers.
Industry RankSector Rank
ROA -54.03%
ROE -68.07%
ROIC N/A
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
CRBU Yearly ROA, ROE, ROICCRBU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

CRBU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBU Yearly Profit, Operating, Gross MarginsCRBU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

CRBU does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRBU has more shares outstanding than it did 1 year ago.
CRBU has more shares outstanding than it did 5 years ago.
CRBU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRBU Yearly Shares OutstandingCRBU Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRBU Yearly Total Debt VS Total AssetsCRBU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -2.51, we must say that CRBU is in the distress zone and has some risk of bankruptcy.
CRBU's Altman-Z score of -2.51 is in line compared to the rest of the industry. CRBU outperforms 50.99% of its industry peers.
There is no outstanding debt for CRBU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.51
ROIC/WACCN/A
WACC9.05%
CRBU Yearly LT Debt VS Equity VS FCFCRBU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

CRBU has a Current Ratio of 7.63. This indicates that CRBU is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.63, CRBU is in the better half of the industry, outperforming 68.76% of the companies in the same industry.
A Quick Ratio of 7.63 indicates that CRBU has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.63, CRBU is doing good in the industry, outperforming 69.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.63
Quick Ratio 7.63
CRBU Yearly Current Assets VS Current LiabilitesCRBU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for CRBU have decreased strongly by -11.72% in the last year.
Looking at the last year, CRBU shows a very negative growth in Revenue. The Revenue has decreased by -70.31% in the last year.
Measured over the past years, CRBU shows a quite strong growth in Revenue. The Revenue has been growing by 11.54% on average per year.
EPS 1Y (TTM)-11.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.52%
Revenue 1Y (TTM)-70.31%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%-3.13%

3.2 Future

CRBU is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.70% yearly.
Based on estimates for the next years, CRBU will show a very strong growth in Revenue. The Revenue will grow by 168.84% on average per year.
EPS Next Y15.96%
EPS Next 2Y11.58%
EPS Next 3Y11.5%
EPS Next 5Y8.7%
Revenue Next Year-5.74%
Revenue Next 2Y57.09%
Revenue Next 3Y42.29%
Revenue Next 5Y168.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRBU Yearly Revenue VS EstimatesCRBU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
CRBU Yearly EPS VS EstimatesCRBU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRBU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRBU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBU Price Earnings VS Forward Price EarningsCRBU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBU Per share dataCRBU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.58%
EPS Next 3Y11.5%

More info and screens

0

5. Dividend

5.1 Amount

CRBU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARIBOU BIOSCIENCES INC

NASDAQ:CRBU (6/16/2025, 4:30:00 PM)

After market: 1.13 +0.01 (+0.89%)

1.12

+0.01 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)N/A N/A
Inst Owners52.51%
Inst Owner Change-11.69%
Ins Owners4.34%
Ins Owner Change19.94%
Market Cap104.16M
Analysts82.67
Price Target9.62 (758.93%)
Short Float %11.43%
Short Ratio8.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.88%
Min EPS beat(2)4.73%
Max EPS beat(2)9.04%
EPS beat(4)4
Avg EPS beat(4)10.24%
Min EPS beat(4)4.73%
Max EPS beat(4)17.12%
EPS beat(8)6
Avg EPS beat(8)12.46%
EPS beat(12)9
Avg EPS beat(12)8.8%
EPS beat(16)11
Avg EPS beat(16)-37.69%
Revenue beat(2)1
Avg Revenue beat(2)14.26%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)31.82%
Revenue beat(4)2
Avg Revenue beat(4)1.09%
Min Revenue beat(4)-35.93%
Max Revenue beat(4)31.82%
Revenue beat(8)4
Avg Revenue beat(8)77.32%
Revenue beat(12)7
Avg Revenue beat(12)56.38%
Revenue beat(16)7
Avg Revenue beat(16)28.15%
PT rev (1m)-12.29%
PT rev (3m)-28.84%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)14.44%
EPS NY rev (1m)0%
EPS NY rev (3m)28.36%
Revenue NQ rev (1m)33.33%
Revenue NQ rev (3m)-10.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.5
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 0.48
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0.11
BVpS2.34
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.03%
ROE -68.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 102.1%
Cap/Sales 45.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.63
Quick Ratio 7.63
Altman-Z -2.51
F-Score2
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)283.95%
Cap/Depr(5y)220.75%
Cap/Sales(3y)43.03%
Cap/Sales(5y)30.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.52%
EPS Next Y15.96%
EPS Next 2Y11.58%
EPS Next 3Y11.5%
EPS Next 5Y8.7%
Revenue 1Y (TTM)-70.31%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%-3.13%
Revenue Next Year-5.74%
Revenue Next 2Y57.09%
Revenue Next 3Y42.29%
Revenue Next 5Y168.84%
EBIT growth 1Y-24.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.31%
EBIT Next 3Y26.59%
EBIT Next 5YN/A
FCF growth 1Y-35.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.63%
OCF growth 3YN/A
OCF growth 5YN/A